C ardiac regeneration using cell-based therapy is faced with the dilemma of identifying the ideal type of cells for transplantation into the infarcted heart. Besides suboptimal protocols of cell culture and transplantation, ease and availability of cells in sufficient number, their survival in the infarcted region and differentiation into morphofunctional cardiomyocytes for regeneration are some of the major challenges facing the heart stem cell therapy. Despite progress to clinical application, the use of stem cells has not been without controversies regarding their differentiation potential and ability to integrate with the host myocardium. [1] [2] [3] [4] Embryonic stem (ES) cells are the prototypical stem cells that unarguably possess near-ideal characteristics in terms of clonality, self-renewal, and multipotentiality. 5 However, moral and ethical issues regarding availability and immunologic concerns have hampered their progress to clinical use.
The reprogramming of somatic cells with 4 stemness factors, called induced pluirpotent stem cells (iPS cells), has generated alternative sources of stem cells that possess characteristics reminiscent of ES cells in terms of cell biology and pluripotent differentiation characteristics, albeit with availability in large numbers without ethical issues and having better immunologic behavior. 6 Although the main focus of the current research in iPS cell technology pertains to refinement of the protocols to enhance the efficiency of reprogramming and to circumvent the safety issues for their human use, 7 there are few studies that have shown their regenerative potential in vivo in general and for the infarcted myocardium in particular. Terzic's group has taken the lead in this regard to show the reparability of mouse fibroblastderived iPS cells in an immunocompetent mouse heart model of acute myocardial infarction. 8 The authors have demonstrated that the transplanted undifferentiated iPS cells survived in the infarcted myocardium, and by 4 weeks, global heart function was recovered better than basal Dulbecco's modified Eagle's medium (DMEM)-injected control animals. The authors further reported no observation of teratomas in iPS cell-treated animal hearts. We have successfully generated mouse skeletal myoblast (SM)-derived iPS cells (SiPS), which expressed endogenous markers of stemness similar to mouse ES cells. We report that cardiomyocytes derived from the 10-day-old spontaneously beating embryoid bodies (EBs) obtained from SiPS (SiPS-CM) provide an excellent donor cell source that significantly attenuated infarct size expansion and improved contractile heart function in an experimental mouse model of acute myocardial infarction. Moreover, contrary to previous claims, 8 we observed that SiPS transplanted in the infarcted heart of immunocompetent recipient were teratogenic.
Methods

Isolation of Mouse SMs
For our animal experiments, we used the Oct4/GFP transgenic mouse strain (Jackson Laboratories, Bar Harbor, ME) with GFP tagged to the endogenous Oct3/4 gene promoter. For SMs isolation, we followed the standard protocols routinely used in our laboratory as described in the Online Supplement at http://circres.ahajournals.org. 9
Generation and Maintenance of SiPS
Retroviral vectors encoding for Yamanaka's quartet of pluripotentcy-determining factors were purchased from Addgene Inc. (Cambridge, MA) (Addgene plasmid #13367; #13366; #13370; #17220 from Takahashi et al). 6 SMs from Oct4/GFP mice were seeded at a density of 1ϫ10 5 cells/well in a 6-well plate. Twentyfour hours later, the cells were transduced with infectious supernatants from the respective vectors encoding for Oct4, Sox2, Klf4, and c-Myc factors for 48-hour transduction. Subsequently, the cells were replated in a 10-cm cell culture dish on mouse embryonic fibroblasts (MEFs) and observed for development of SiPS clones until 3 weeks. The GFP ϩ SiPS clones with ES cell-like morphology were mechanically incised, cultured on mouse feeder cells, and expanded individually in ES cell culture medium for use in further experiments. For confirmation of pluripotency induction, SiPS were fixed with 3% paraformaldehyde, permeabilized and stained with antistage-specific embryonic antigen-1 (SSEA-1) antibody. The primary antigenantibody reaction was detected with goat antimouse Alexa Fluor-568 conjugated secondary antibody (1:200; Cell Signaling Tech, Danvers, MA). Nuclei were visualized by 4,6Ј-diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA) staining. The murine SiPS clone Raf1 was expanded on mitotically inactivated murine embryonic fibroblasts (MEFs; 5ϫ10 4 cells/cm 2 ) as described in the Online Supplement.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Isolation of total RNA, and their subsequent first-strand cDNA synthesis, was performed using an RNeasy mini kit (Qiagen, Valencia, CA) and an Omniscript Reverse Transcription kit (Qiagen, Valencia, CA), respectively, per the instructions of the manufacturer and as described earlier. 10 The primer sequences used are given in Online Table I .
Alkaline Phosphatase Staining and Immunocytochemistry
Alkaline phosphatase staining was done as per the manufacturer's instruction using Alkaline Phosphatase Detection kit (Millipore SCR004).
The undifferentiated colonies of iPS and ES cells were immunostained for the expression of the stage-specific embryonic antigen-1 (SSEA-1), Oct3/4, and Sox2 as described in the Online Supplement. The immunostained cells were observed and photographed with a microscope equipped for epifluorescence (Olympus, Tokyo, Japan).
Teratoma Formation and Karyotyping
Teratogenicity of SiPS was assessed in immunodeficient mice (nϭ3) as described in the Online Supplement. Karyotyping was carried out with quinacrine-Hoechst staining at the Transgenic Facility of the University of Kansas Medical Center (Kansas City, KS).
Spontaneous Cardiac Differentiation of SiPS
For differentiation into cardiomyocytes, SiPS were grown in suspension culture for 3 days in high-glucose DMEM containing 15% FBS, 5 mmol/L penicillin/streptomycin and 5 mmol/L nonessential amino acids. After 3 days in suspension culture, rounded EBs were formed, which were seeded on gelatin-coated dishes and cultured for 10 days. Adherent spontaneously contracting colonies were mechanically dissected and dissociated into single cardiomyocytes for use in further experiments.
miR Analysis of SiPS and SiPS-CM
Total RNA from SMs, SiPS, and SiPS-CM were labeled with Cy3. Samples were hybridized to a mouse miRNA microarray (LC Science, Houston, TX), according to manufacturer's protocol. 
Nonstandard Abbreviations and Acronyms
Ultrastructural Studies
Ultrastructural studies were performed on the myocardial tissue samples as described in the Online Supplement using JEOL transmission electron microscope.
Experimental Animal Model and SiPS Engraftment
The present study conformed to the Guide for the Care A model of acute myocardial infarction was developed in allogenic 8-to 12-week-old female C57BL/6J immunocompetent mice as described earlier. 11 Briefly, the animals were anesthetized (Ketamine/Xylazine 0.05 mL intraperitoneally), intubated, and mechanically ventilated (Harvard Rodent Ventilator, Model 683). Minimally invasive thoracotomy was performed for permanent ligation of coronary artery with a Prolene #9 to 0 suture. Myocardial ischemia was confirmed by color change of left ventricular wall. The animals were grouped (nϭ12 per group) for intramyocardial injection of 10 L of basal DMEM without cells (group 1) or containing 3ϫ10 5 SMs (group 2), SiPS (group 3), and SiPS-CMs (group 4). Additionally, young female transgenic Oct4/GFP (C57BL/6x129S4SV/jae) (nϭ4) animals were used for transplantation of SiPS in group 3 to ascertain whether the use of isogenic recipient could curtail tumorgenic potential of SiPS. The cells were injected 10 minutes after coronary artery ligation at multiple sites (3 to 4 sites per heart) in the free wall of the LV under direct vision. For postengraftment tracking of the transplanted cells and determination of their fate, the cells were labeled with Q-tracker ® -625 (red fluorescence; Invitrogen, Carlsbad, CA). The chest was closed and the animals were allowed to recover. Subsequently, the animals were injected Buprinex (0.05 mL subcutaneously) during the first 24 hours to alleviate pain and were maintained until 4 weeks before euthanasia and recovery of the heart tissue samples.
Transthoracic Echocardiography
The animals (nϭ8 in groups 1, 2, and 3 each and nϭ11 in group 4) were anesthetized, and transthoracic echocardiography was performed as detailed in the Online Supplement.
Histological and Immunohistological Studies
The animals were euthanized at 7 days and 4 weeks after heart function studies. The heart tissue samples were removed and used for histological and immunohistological studies as described earlier. 12 
Results
Overexpression of Stemness Factors and SMs Reprogramming
The SMs were characterized for purity by flow cytometry for desmin expression (On-Line Figure II 
In Vitro Predifferentiation of Cardiac Progenitors From SiPS for Transplantation
Of the 2 murine SiPS clones, ie, Raf1 and Raf2, characterized in vitro for pluripotency, Raf1 was differentiated by a standard EB-based differentiation protocol. Between days 3 and 5 in differentiation culture medium, the floating EBs were transferred to adherent culture conditions in which the cells were cultured for 5 to 6 days. By day 10 after initiation of differentiation, few spontaneously beating areas were observed that continued to increase and expand with longer time maintenance of the culture (Online Movie I). Such synchronous contractile activity in SiPS-CMs was observed for up to 3 to 4 weeks. Profiling of cardiac specific genes was performed for characterization of the spontaneously beating EBs (Figure 2 ). We observed multifold increase in cardiacspecific genes expression in 10-day-old beating EBs, including maturation markers ␣-MHC, ␤-MHC, and cardiac troponin-I in comparison with SiPS and Nat SMs ( Transmission electron microscopy revealed ultrastructural features of the developing cardiomyocytes in SiPS-CMs with fully developed sarcomeres and ribosomes ( Figure 3 , A through C). Tight junctions between adjacent SiPS-CMs were also observed in the spontaneous beating regions in the culture (indicated by red arrows; Figure 3C ).
Prevention/Reduction of Tumorgenicity by Predifferentiated Cardiac Progenitors
As published in our first report on teratogenicity of SiPS in which 6 of the 16 SiPS-transplanted animals developed cardiac tumors, 13 no tumor formation was observed in any other group included in the present study. Figure 4C is a representative echocardiograph of an animal heart that developed cardiac tumor in the LV 4 weeks after SiPS transplantation. Histological studies confirmed that these tumors consisted of cells from the 3 germ layers. 13 Transmission electron microscopy revealed regions with myogenic differentiation identified on the basis of their typical striated muscle fiberlike structure with sarcomeric organization ( Figure 4D ). Moreover, comparative miRNA profile revealed that cardiomyocytes isolated from SiPS expressed tumor suppressive miRs 125b, 16, 199a, 214, 26a, 200b, and 200c in abundance when compared with SiPS ( Figure 5 ). These results suggest that directed differentiation of iPS cells prior to transplantation is highly desirable to prevent tumor formation.
Histological Benefits of SiPS and Their Derivatives
Histochemical studies on the animal hearts from various treatment groups (nϭ4 per group), 4 weeks after their respective treatment, were performed on at least 2 middle slices of the heart. We observed extensive myocyte damage in the LV, which was replaced by scar tissue and thinning of the LV wall was reduced in all the treatment groups ( Figure 4) . However, all the cell treatment groups had significantly attenuated infarct size in comparison with DMEM-injected controls (41.3%Ϯ1.3%). However, infarct size between cell treatment groups did not show significant difference despite the fact that SiPS-CMstreated animal hearts had the smallest infarct size (23.9%Ϯ3.1%) in comparison with SMs (25.9Ϯ1.8) and SiPS treated (26Ϯ3.3). Architectural analysis of hematoxylin-eosin-stained cardiac tissues had extensive presence of islands of myofibers in the infarcted hearts of the cell-treated groups (Figure 4) . Four weeks after cell transplantation, Q-dot-labeled cells were observed in the infarct and peri-infarct areas in the LV ( Figure 6A ). Immunohistochemistry for cardiac troponin-I and Cx-43 was performed to determine the fate and integration of the transplanted cells in the heart. Colocalization of Q-dots (red fluorescence) with cardiac troponin-I (green fluorescence) in the infarct and peri-infarct regions in the SiPSCMs-transplanted animal hearts indicated their myogenic differentiation ( Figure 6 , B through D), which formed gap junctions with the host myocytes ( Figure 6 , E and F).
Heart Function Studies
Permanent LAD coronary artery ligation led to significant deterioration in the indices of LV contractile function, including LVEF and LVFS in comparison with the baseline values (nϭ4; 74.2Ϯ2.6; 36.7%Ϯ2.2%, respectively). Transplantation of Nat SMs, SiPS, and SiPS-CMs significantly preserved the global pump function of the infarcted myocardium ( Figure 7 
Discussion
The breakthrough discovery that somatic cells could be reprogrammed to pluripotent status has generated immense interest in pluripotent stem cells because of their vast therapeutic applications. Thus, the prospect of using iPS cells has added new dimensions to stem cell-based therapy. We report reprogramming of mouse SMs and their application for cardiac repair following myocardial infarction in comparison with SiPS and Nat SMs. Our results avidly showed the superiority of allogenic SiPS-CMs in terms of safety and regenerative capacity in an immunocompetent mouse model of acute myocardial infarction. The major findings of the study are that (1) SMs can be easily reprogrammed to develop iPS cells; (2) undifferentiated iPS cells are tumorgenic in immunocompetent hosts; (3) directed differentiation of iPS cells to derive cardiac progenitors circumvent their tumorgenicity following transplantation in immunocompetent recipients; and (4) we provide a comparative miR expression profile in Nat SMs, SiPS, and SiPS-CMs that essentially determined the pluripotent status of SiPS during reprogramming of SMs and showed an upregulated expression of tumor-suppressive miRs in differentiated cardiac cells.
The rationale to reprogram SMs was based on our results that SMs endogenously expressed 3 (ie, Sox2, cMyc, and Klf4) of the Yamanaka's quartet of transcription factors required for reprogramming, 6 thus making these cells an easier choice for reprogramming than were the terminally differentiated fibroblasts. It is highly likely that reprogramming SMs would require fewer factors. 14 Second, it is anticipated that iPS cells carry forward the epigenetic memory of the somatic cells of their origin. 15 Therefore, SMs that possess inherent myogenic potential would be a better choice for reprogramming than would the nonmyogenic fibroblasts. Despite the presence of 3 of the 4 required stemness factors, the use of Oct4 alone did not induce pluripotency in SMs. It appears that there is an optimum threshold level of expression for each of these factors that is required to ensure reprogramming of SMs. A recent study has shown that SMs can be reprogrammed using Yamanaka's quartet of stemness factors with simultaneous suppression of MyoD in the reprogrammed cells, which substantiates our results. 15 However, the authors did not show their cardiac differentiation capability in vitro as well as in an experimental animal model. In an interesting study, neurospheres were obtained from mouse iPS cell lines derived from embryonic fibroblasts, adult tail-tip fibroblasts, hepatocytes, and stomach epithelial cells 16 and evaluated the teratogenicity of the secondary neurospheres. Interestingly, iPS cells of different tissue origins differed in their teratogenicity, which also correlated well with the presence of undifferentiated iPS cells in the neurospheres. These data support our notion that certain somatic cell types may be superior choices for reprogramming and would also influence the subsequent differentiation potential of their derived iPS cells. Another important consideration in the selection of SMs for reprogramming was that the choice of cell may impact the tumorgenicity of their derived iPS cells. Moreover, SMs have been extensively studied for myocardial repair in both experimental animal models and human patients. 17, 18 However, their lack of functional integration postengraftment in the heart and the issues of arrhythmogenicity have marred their clinical applicability. 19 We believe that reprogrammed SMs would provide an excellent autologous source of cells for transplantation.
Since inception of the iPS cell technology, in vivo cardiomyogenic potential of iPS cells has been mostly studied after their blastocyst injection. 20, 21 The injected iPS cells differentiated into mature cardiomyocytes in the chimeric heart. These data were well supported by in vitro experimental studies that examined the cardiomyogenic potential of ES cells. 20, 22 Molecular studies demonstrated upregulation of mesodermal gene and protein markers of cardiac differentiation, which was confirmed by fluorescence immunostaining and ultrastructural studies. Similar to ES cells, iPS cells can differentiate into functionally competent cardiomyocytes, 23 however, very few studies showed that iPS cells regenerated the infarcted myocardium after transplantation. Terzic et al have reported improved global cardiac function in iPS celltreated mice, however, without substantiating cardiogenesis in the infarcted mice heart with immunohistological evidence. 8 Given the tumorgenic nature of pluripotent stem cells, it is important to ensure that the transplantation of SiPS is free of undifferentiated cells, 24 which are potential contributors of tumorgenicity of iPS cells. 16 Even the use of isogenic animals for transplantation of SiPS failed to curtail their teratogenic characteristics in the heart. Isolation of specific subtypes of SiPS with no oncogenic tendency will also help to curtail tumorgenicity of SiPS. Figure 4C . E, The magnified image of the boxed area (red) in Figure  4D (original magnificationϭ12500ϫ).
In view of difficulties in using iPS cell-based cell therapy, we hypothesized that predifferentiation or guided differentiation of SiPS would be a safer and effective approach for transplantation. We therefore opted to transplant 8-to 10-day-old EBs that contained developing and beating myocytes. We observed increased myogenesis in SiPS-CMs transplanted hearts and, more important, without incidence of tumor formation as against significantly higher number of animals (nϭ4) developing tumors in SiPS transplanted hearts. Because the number of cells transplanted in group 3 and group 4 were similar, contribution of residual SiPS population toward improved cardiac function would be marginal. Strategies to enhance the purity of SiPS-CMs and to exclude the presence of undifferentiated SiPS are therefore warranted. Directed differentiation protocols will require optimal pretreatment of SiPS with specific cytokines, growth factors, or small molecules rather than the use of spontaneous differentiation, which may lack reproducibility.
Our study provides the first ever miR expression profiling of SMs during the process of reprogramming and differentiation. The miRs are global regulators of stem cell functions, including their differentiation capacity. 25 Significant changes were noticed in the expression pattern of miR let-7, miR-200, and miR-290 families that largely varied with the differentiation status of the cells. Upregulation of let-7 family of miRs is associated with differentiation status rather than type of the cell. 26 We observed that let family of miRs including let7 a-g, i, and miR-98 were down-regulated in SiPS in comparison with Nat SMs. Nevertheless, there was an obvious increase in their expression during myogenic differentiation of SiPS. The 5-member miR-200 family (miR-200a-c, miR-141, and miR-429) also showed a similar trend. Of these members, miR200a-c were not detected in either Nat SMs or SiPS; however, their expression increased in SiPS-CMs, which indicated the incomplete differentiation status of SMs. 26 Besides these 2 important miR families, SiPS also expressed other signature ES cell miRs-including miR-290, 292, and 293-,that are not only regulated by pluripotency genes Oct4, Nanog and Sox2 but also target these genes in "incoherent feed-forward loops." These data reflected similarity of miR expression profiles between SiPS and ES cells. Similarly, some other miRs with significantly altered expression during transition of SMs to SiPS and then onward differentiation into cardiomyocytes included miR-23a and 23b (regulated by cMyc), 27 miR-214 (part of regulatory circuit controlling differentiation and cell fate decision), 28 and miR-21, a known suppressor of Nanog, Sox2, and Oct4, 25 that showed substantial increase following cardiomyogenic differentiation of SiPS. The miR-24 a ubiquitously expressed miRNA, has an antiproliferative effect independent of p53 function 29 and was inhibited in SiPS in Whereas left ventricle ejection fraction (LVEF) and left ventricle fractional shortening (LVFS) were significantly deteriorated in DMEM-injected control animal hearts, cell therapy, irrespective of the type of the cell injected, preserved the contractile function of the heart (PϽ0.05 versus DMEM injected control). However, significant improvement in LVEF and LVFS was observed in SiPS-CM treatment group. Similarly, LV chamber dimensions during diastole (LVIDd) and systole (LVIDs) were better preserved in the cell transplanted animal hearts than in the controls, thus indicating prevention of pathological remodeling.
comparison with SMs and SiPS-CMs. Moreover, miR-26a is a muscle-specific miR that is up-regulated during myogenesis 30 and was up-regulated both in SMs and in SiPS-CMs in comparison with the SiPS. Let-7, miR-125b, miR-16, miR-199a, miR-214, miR-26a, miR-200b, and miR-200c are among the tumor-suppressive miRs that are significantly up-regulated in SiPS-CM. [31] [32] [33] All these data clearly reflect not only the similarity between miR expression profile of ES cells and SiPS during reprogramming of SMs but also up-regulation of tumor-suppressive miRs in SiPS-CMs in comparison with SiPS.
In conclusion, the study results indicate SMs as better candidates for reprogramming to pluripotency because of their inherent expression of 3 of the 4 stemness-determining factors. Although the study used conventional retroviral vector-based ectopic expression of 4 stemness factors, intrinsic expression of 3 of the required 4 stemness factors raises the possibility of their reprogramming with a smaller number of factors or even by treatment with nonviral methods for clinical applications. Transplantation of cardiac progenitors predifferentiated from SiPS was optimal for tumor-free cardiogenesis with resultant structural and functional recovery in an immunocompetent animal model of acute myocardial infarction. Given that tumorgenesis is a time-dependent process, it would be prudent to carry out longer-term studies to assess tumorgenic potential of SiPS-CMs besides designing more systematic studies for guided differentiation of SiPS for transplantation.
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